Following a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.
London-based orphan drug developer AMO Pharma’s drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy.
French drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers.
Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications.
British Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed using technology, which was licenced from Abzenawhich was licenced from Abzena.
Following the EMA’s recommendation for EU approval of sarilumab as second-line treatment for rheumatoid arthritis, French drug giant Sanofi and partner Regeneron have also been given the green light from the US FDA.
Top-Line Phase 3 data of Amgen’s/UCB’s osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal.
Luxembourg-based venture capital specialist Vesalius Biocapital has closed the first round of Biocapital III fund that aims to invest into later-stage European life sciences companies.
German Merck KGaA has developed a new genome editing tool dubbed proxy-CRISPR providing access to previously inaccessible microenviroments of the genome by modification of chromatin modifications.
Astellas Pharma Inc. has completed the acquisition of Ogeda SA (previously Euroscreen SA, Gosselies, Belgium).